Public Release: 

Blood stem cell transplant from a relative better option for children with leukaemia

Early online publication: Thursday August 4, 2005 - EMBARGO: 6:30pm ET Wednesday August 3, 2005


Children with very high-risk acute lymphoblastic leukaemia (ALL) benefit if they receive a blood stem cell transplant from a compatible related donor rather than chemotherapy, according to an article being published online today by THE LANCET.

ALL is the main type of leukaemia affecting children. High-risk childhood ALL is defined by various biological characteristics at onset or by resistance to treatment. High dose chemotherapy is the standard treatment for children with high-risk ALL but in most cases the prognosis is poor.

Adriana Balduzzi (Universita' degli Studi di Milano Bicocca, Italy) and colleagues did a randomised trial to compare chemotherapy with transplantation in patients in first complete remission--when there is no sign of the cancer on the patient's medical scans. Between 1995 and 2000 the investigators recruited patients younger than 18 years with newly diagnosed ALL onto the study. Centres from seven countries took part in the study. 357 children entered the study, 280 were assigned chemotherapy and 77 were assigned to blood stem cell transplant on the basis that there was an available compatible related donor. The researchers found that the 5-year disease-free survival was 41% in the chemotherapy group and 57% in the blood stem cell transplant group. 5-year survival was 50% for the chemotherapy group and 56% for the transplant group.

Dr Balduzzi states: "This international study has shown that availability of a compatible related donor for children with very-high risk acute lymphoblastic leukaemia in first complete remission improves disease-free survival;....the gap between the two strategies increased as the risk profile of the patient worsened".


Contact: Dr Adriana Balduzzi, Clinica Pediatrica, Universita' degli Studi di Milano Bicocca, Ospedale San Gerardo, Via Pergolesi 33, 20052 Monza (Milano), Italy. T) 39-039-233-2442

The Lancet press office T) 44-207-424-4949/4249

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.